Bal Pharma Ltd (BALPHARMA) Financials - Quarterly Results, Profit & Loss, Balance Sheet, Cash Flow Bal Pharma Ltd reported sales of ₹88.62 Cr, operating profit of ₹7.95 Cr (OPM 8.97%) and net profit of ₹1.13 Cr for the quarter ended Jun 2026. Figures in ₹ crore, consolidated where available.
BALPHARMA quarterly results (₹ Cr) Metric Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sales 73.69 73.15 81.88 65.87 74.02 87.69 84.08 88.62 Expenses 66 65.4 74.24 59.81 68.29 78.15 73.5 80.67 Operating Profit 7.69 7.75 7.64 6.06 5.73 9.54 10.58 7.95 OPM 10.44% 10.59% 9.33% 9.2% 7.74% 10.88% 12.58% 8.97% Other Income -0.2 0.51 1.08 0.72 1.12 0.33 -0.24 0.44 Interest 3.65 5.01 3.95 4.05 3.86 4.85 4.06 4.47 Depreciation 2.48 2.69 2.18 2.52 2.27 3.23 3.06 2.78 Profit before tax 1.36 0.56 2.59 0.21 0.72 1.79 3.22 1.14 Tax 23.53% 7.14% -108.88% 0% 0% 0% -12.11% 0% Net Profit 1.04 0.52 5.41 0.21 0.72 1.79 3.6 1.13 EPS in Rs 0.65 0.3 3.41 0.13 0.45 1.12 2.25 0.7
BALPHARMA profit & loss, annual (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM Sales 281 304 339 303 312 334 Expenses 257 279 308 273 280 301 Operating Profit 24 25 31 30 32 34 OPM 9% 8% 9% 10% 10% 10% Other Income 5 1 3 2 2 2 Interest 11 12 15 17 17 17 Depreciation 9 9 10 10 11 11 Profit before tax 9 5 9 5 6 7 Tax 38% 45% 18% -41% -7% - Net Profit 6 3 7 7 6 7 EPS in Rs 3.78 1.64 4.68 4.53 3.94 4.52 Dividend Payout 26% 61% 26% 26% 30% -
BALPHARMA balance sheet (₹ Cr) Metric Mar 2023 Mar 2024 Mar 2025 Sep 2025 Mar 2026 Equity Capital 16 16 16 16 16 Reserves 48 56 62 62 66 Borrowings 131 140 150 155 160 Other Liabilities 116 108 108 116 134 Total Liabilities 311 320 336 349 376 Fixed Assets 76 80 87 92 94 CWIP 0 0 3 3 7 Investments 0 7 2 0 2 Other Assets 235 233 244 253 272 Total Assets 311 320 336 349 376
BALPHARMA cash flows (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Cash from Operating Activity 27 -2 23 20 30 Cash from Investing Activity -9 -22 -19 -15 -21 Cash from Financing Activity -17 24 -1 -8 -10 Net Cash Flow 0 0 3 -2 0 Free Cash Flow 18 -16 12 2 8 CFO/OP 117% -4% 88% 75% 95%
BALPHARMA ratios Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Debtor Days 98 113 107 111 110 Inventory Days 162 207 167 238 269 Days Payable 143 167 147 189 206 Cash Conversion Cycle 117 153 127 161 173 Working Capital Days 18 13 12 6 7 ROCE 12% 10% 12% 10% 10%